Melanoma Clinical Trial

IL-2 “SELECT” Tissue Collection Protocol in Patients With Advanced Melanoma

Summary

The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.

View Full Description

Full Description

Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Malignant melanoma that is metastatic or unresectable
Eligible to receive high-dose IL-2
Tissue block available with adequate tumor to perform RNA extraction and DASL analysis

Exclusion Criteria:

Prior immunotherapy for unresectable or metastatic disease
Untreated brain metastases, leptomeningeal disease, or seizure disorder

Study is for people with:

Melanoma

Estimated Enrollment:

153

Study ID:

NCT01288963

Recruitment Status:

Completed

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

153

Study ID:

NCT01288963

Recruitment Status:

Completed

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.